Jeffrey Mann Purchases 20,000 Shares of Embecta (NASDAQ:EMBC) Stock

Posted by Stanley Muller on Aug 13th, 2026

Embecta Corp. (NASDAQ:EMBC – Get Free Report) insider Jeffrey Mann purchased 20,000 shares of Embecta stock in a transaction on Wednesday, August 12th. The stock was bought at an average cost of $4.99 per share, for a total transaction of $99,800.00. Following the transaction, the insider directly owned 262,915 shares in the company, valued at $1,311,945.85. This represents a 8.23% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Embecta Price Performance

Shares of EMBC traded up $0.41 during midday trading on Thursday, reaching $5.16. The stock had a trading volume of 659,113 shares, compared to its average volume of 1,586,592. The company has a market cap of $292.08 million, a price-to-earnings ratio of 3.48 and a beta of 0.81. The company’s fifty day simple moving average is $3.43 and its two-hundred day simple moving average is $6.46. Embecta Corp. has a 1-year low of $2.77 and a 1-year high of $15.55.

Embecta (NASDAQ:EMBC – Get Free Report) last posted its earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, beating the consensus estimate of $0.27 by $0.29. The firm had revenue of $271.70 million for the quarter, compared to analyst estimates of $254.53 million. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.Embecta’s revenue for the quarter was down 8.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.12 earnings per share. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, sell-side analysts forecast that Embecta Corp. will post 1.85 earnings per share for the current year.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Thursday, August 27th will be paid a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a yield of 0.8%. The ex-dividend date is Thursday, August 27th. Embecta’s dividend payout ratio (DPR) is currently 2.70%.

Hedge Funds Weigh In On Embecta

Institutional investors and hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC increased its holdings in shares of Embecta by 368.6% in the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock valued at $28,000 after purchasing an additional 1,574 shares in the last quarter. One Wealth Advisors LLC purchased a new stake in Embecta during the second quarter worth about $33,000. Tower Research Capital LLC TRC grew its position in Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock worth $71,000 after buying an additional 6,224 shares during the period. Wexford Capital LP purchased a new position in Embecta in the third quarter valued at about $94,000. Finally, Humankind Investments LLC acquired a new stake in shares of Embecta during the 2nd quarter valued at approximately $111,000. 93.83% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Embecta

Here are the key news stories impacting Embecta this week:

Negative Sentiment: The lawsuit, filed in federal court in New Jersey, alleges that Embecta and certain executives misrepresented the commercial stability of the company’s insulin pen-needle business. The allegations concern investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, and have not been proven in court. EMBC Securities Lawsuit: Embecta Securities Fraud Class Action is Pending
Negative Sentiment: A wave of investor-alert releases from SBS Law, Kaplan Fox, DJS Law, Rosen Law Firm, Hagens Berman, Faruqi & Faruqi and other firms highlights an August 17, 2026 deadline for investors to seek lead-plaintiff status. The repeated announcements increase the visibility of the legal issue and could raise concerns about potential financial, management and reputational costs for Embecta. Kaplan Fox Alerts Investors of a Securities Class Action Against Embecta
Neutral Sentiment: The announcements primarily seek potential plaintiffs and do not represent a new court ruling, settlement or regulatory finding. Embecta’s previously reported quarterly results showed adjusted earnings and revenue above consensus, but revenue declined 8.1% year over year; the company’s FY 2026 earnings guidance remains $1.80–$1.90 per share.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on EMBC shares. Weiss Ratings downgraded Embecta from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, August 3rd. Zacks Research raised Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Bank of America dropped their price objective on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research note on Monday, May 18th. Mizuho decreased their target price on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Wall Street Zen cut Embecta from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Three investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Embecta currently has a consensus rating of “Reduce” and an average price target of $11.00.

View Our Latest Stock Report on EMBC

Embecta Company Profile

(Get Free Report)

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.